BMY vs CNC: fair value comparison
Bristol-Myers Squibb Company and Centene Corporation · Updated 2026-09-06
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, CNC currently sits closer to the top of our discount ranking. BMY carries the stronger quality grade.
| BMY | CNC | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $66.82 | $67.04 |
| 12-month range | $46.02–$66.92 | $33.95–$65.23 |
| Sector rank | #100 of 113 Healthcare | #96 of 113 Healthcare |
| Quality grade | C | F |
| Leverage | High | Moderate |
| Margin trend | Expanding | Contracting |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | — |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: BMY fair value analysis · CNC fair value analysis